Fda-approved inhibitors of rtk/raf signaling potently impair multiple steps of in vitro and ex vivo influenza a virus infections

HIGHLIGHTS

• who: Robert Meineke and collaborators from the Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine in Hannover (TiHo), Bu00fcnteweg, Hannover, Germany have published the paper: FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections, in the Journal: Viruses 2022, 2058 of /2022/
• what: The authors focused the studies on seven inhibitors that showed >1-log10 (10-fold) titer reductions. The authors aimed to identify which steps of the viral infection cycle were affected by each 3.3. 10 of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.